Furthermore, in vivo efficacy study indicated that trastuzumab did not inhibit tumor growth in xenografts expressing the ZNF207-ERBB2 fusion; this finding supported the resistant mechanism to trastuzumab (21). The gene discussed is ERBB2; the disease is neoplasm.